Quince Therapeutics, Inc.

Equities

QNCX

US22053A1079

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 03:42:10 2024-03-28 pm EDT 5-day change 1st Jan Change
1.075 USD -4.87% Intraday chart for Quince Therapeutics, Inc. -4.70% +6.19%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
North American Morning Briefing : Markets Steady -2- DJ
Quince Therapeutics, Inc. Launches Scientific Advisory Board CI
Quince Therapeutics, Inc. Appoints Rajiv Patni to Its Board of Directors CI
North American Morning Briefing : All Eyes on -2- DJ
Quince Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Quince Therapeutics, Inc. Appoints Brendan Hannah to the Position of Chief Operating Officer CI
Quince Therapeutics, Inc. Appoints Luca Benatti as Director CI
Quince Therapeutics, Inc. acquired EryDel S.p.A CI
Quince Says US FDA Lifts Partial Clinical Hold on EryDel's Treatment for Ataxia-Telangiectasia MT
Quince Therapeutics to Advance Study of EryDex as FDA Lifts Application Hold DJ
Quince Therapeutics, Inc. Announces That U.S. Food and Drug Administration Lifts the Partial Clinical Hold on Erydel S.P. A's Investigational New Drug Application for Its Lead Phase 3 Asset, Erydex CI
Quince Therapeutics Appoints Charles S. Ryan as President CI
Insider Buy: Quince Therapeutics MT
Quince Therapeutics, Inc. Announces the Departure of Karen Smith as Chief Medical Officer, Effective September 1, 2023 CI
Quince Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Sector Update: Health Care Stocks Declining Late Monday MT
Sector Update: Health Care Stocks Easing Monday Afternoon MT
Quince Therapeutics to Acquire EryDel in All-Stock Deal MT
Quince Therapeutics, Inc. Announces Board and Executive Changes CI
Quince Therapeutics, Inc. agreed to acquire EryDel S.p.A. for approximately $510 million. CI
Quince Therapeutics Shares Rise Pre-Bell After Echo Lake Capital Raises Acquisition Offer MT
Transcript : Quince Therapeutics, Inc. - Shareholder/Analyst Call
Quince Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Biomed Industries, Inc. submitted a proposal to acquire Quince Therapeutics, Inc. for $94 million. CI
Sector Update: Health Care Stocks Finish Modestly Higher MT
Chart Quince Therapeutics, Inc.
More charts
Quince Therapeutics, Inc. is a late-stage biotechnology company. The Company is engaged in unlocking the patient’s own biology to deliver life-changing therapeutics to those living with rare diseases. The Company’s asset, EryDex, is being developed for the treatment of a rare neurodegenerative disease, Ataxia-Telangiectasia (A-T). EryDex utilizes a technology platform for autologous intracellular drug encapsulation (AIDE). Its proprietary AIDE technology is designed to optimize the biodistribution of dexamethasone sodium phosphate (DSP; a pro-drug) by using an A-T patient’s own red blood cells to deliver the sustained therapeutic over a once-monthly treatment period. The Company is also designed to allow for the chronic administration of the therapeutic. The AIDE technology platform delivers a variety of therapeutics, ranging from small to large molecules, as well as biologics. The Company also intends to investigate additional potential applications of the AIDE technology platform.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
  1. Stock
  2. Equities
  3. Stock Quince Therapeutics, Inc. - Nasdaq
  4. News Quince Therapeutics, Inc.
  5. Cortexyme Completes Phase 1 Single, Multiple Ascending Dose Trial of Potential Alzheimer's Disease Treatment